The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.
Get the most out of
Register for free and enjoy unlimited access to: